A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To evaluate the safety and tolerability of four doses of oral vesnarinone in patients with advanced HIV disease.
Condition or disease
Fourteen patients per dose level receive vesnarinone at 1 of 4 doses for 12 weeks. At least seven patients at a given dose level must have completed 4 weeks of treatment before dose is escalated in subsequent patients.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Chemoprophylaxis for Pneumocystis carinii, candida, mycobacteria, and other opportunistic infections.
Acyclovir for up to 14 days for acute herpes outbreaks.
Patients must have:
Documented HIV infection.
CD4 count 50 - 300 cells/mm3.
No active opportunistic infections.
No fever, diarrhea, or Herpes zoster.
Patients with the following symptoms or conditions are excluded:
Clinically significant current cardiac disease, including patients who exhibit long QTC syndrome on EKG screening and who have an abnormal cardiothoracic ratio on chest x-ray at baseline.
Active malignancy (other than cutaneous Kaposi's sarcoma or cutaneous basal cell carcinoma or in situ carcinoma of the cervix).
Antiretroviral agents, including ddI, ddC, AZT, and d4T.
Investigational HIV drugs/therapies including vaccines.
Interferon or other immunomodulating agents.
Corticosteroids (other than topical).
Agents known to cause neutropenia.
Trimethoprim/sulfamethoxazole in excess of 160 mg trimethoprim and 800 mg sulfamethoxazole thrice weekly.
Patients with the following prior conditions are excluded:
Prior history of cardiac disease.
History of agranulocytosis or severe (grade 3 or worse) drug-induced neutropenia or documented abnormalities in granulocyte function.
AZT, ddI, ddC, d4T, or other nucleoside analog antiretroviral therapy within 14 days prior to study entry.
Prior cytotoxic chemotherapy.
Acyclovir for herpes prophylaxis within 48 hours prior to study entry.
Excluded within 30 days prior to study entry:
Erythropoietin, transfusion, or blood product use.
Radiation therapy (including electron beam irradiation). Active use of illicit drugs (specifically cocaine, amyl nitrate, heroin, and other cardioactive agents).